Apimeds Pharmaceuticals US (APUS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Apimeds Pharmaceuticals US used $8.93M of cash in operating activities and spent $57.33K on capital expenditures. That left free cash flow of −$8.98M.

Apimeds Pharmaceuticals US Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Apimeds Pharmaceuticals US, Inc. (APUS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Operating Activities
Net Income	-6.00	-1.39	-0.78	-0.67	-1.03
Depreciation & Amortization	0.01	0.00	0.00	0.00	0.00
Stock Based Compensation	3.27	0.00	0.07	0.19	0.19
Change in Working Capital	-2.82	0.54	0.04	0.00	0.00
Change in Accounts Payable	0.00	0.00	0.00	0.00	0.00
Change in Other Working Capital	2.71	0.54	0.04	0.00	0.01
Other Operating Activities	2.71	0.12	0.04	0.03	0.01
Net Cash from Operating Activities	-8.93	-0.73	-0.63	-0.45	-0.82
Investing Activities
Capital Expenditures	-0.06	0.00	0.00	0.00	0.00
Purchases of Investments	-2.00	0.00	0.00	0.00	0.00
Other Investing Activities	-8.00	0.00	0.00	0.00	0.00
Net Cash from Investing Activities	-10.06	0.00	0.00	0.00	0.00
Financing Activities
Debt Repayment	9.30	0.25	0.00	0.26	0.40
Common Stock Issued	11.63	0.00	1.06	0.00	0.00
Other Financing Activities	-1.26	0.08	-0.02	0.02	0.00
Net Cash from Financing Activities	20.62	0.33	1.03	0.28	0.40
Summary
Effect of Forex Changes on Cash	8.00	0.00	0.00	0.00	0.00
Net Change in Cash	1.63	-0.41	0.40	-0.17	-0.42
Cash at Beginning of Period	0.00	0.41	0.01	0.17	0.59
Cash at End of Period	9.64	0.00	0.41	0.01	0.17
Free Cash Flow	-8.98	-0.73	-0.63	-0.45	-0.82

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Apimeds Pharmaceuticals US Cash Flow

What is Apimeds Pharmaceuticals US's free cash flow?

Apimeds Pharmaceuticals US had negative free cash flow of $8.98M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$8.93M minus $57.33K of capital expenditures.

How much does Apimeds Pharmaceuticals US spend on capital expenditures?

Apimeds Pharmaceuticals US spent $57.33K on capital expenditures in fiscal 2025.

Does Apimeds Pharmaceuticals US pay dividends or buy back shares?

Apimeds Pharmaceuticals US's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition